Narrowing the Gaps in Global Disputes: the Case of Counterfeits in Kenya

Studies in Comparative International Development

Volumn 50, Issue 2, 2015, Pages 157-186

  Chorev, Nitsan ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Counterfeit; Intellectual property rights; Kenya; Path dependence

Indexed keywords

INTELLECTUAL PROPERTY RIGHTS; LEGAL SYSTEM; MONOPOLY; REGIONAL DEVELOPMENT;

KENYA;

EID: 84930414687     PISSN: 00393606     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12116-015-9183-5     Document Type: Article

References (76)

1. Abbott A. Sequences of social events: concepts and methods for the analysis of order in social processes. Hist Methods. 1983;16(4):129–47.
2. Abbott FM, Reichman JH. The Doha round’s public health legacy: strategies for the production and diffusion of patented medicines under the Amended Trips Provisions. J Int Econ Law. 2007;10(4):921–87.
3. Agence France-Presse. GlaxoSmithKline Urges Kenya to Block Fake Medicines. 2008, April 15. Available at http://www.google.com/hostednews/afp/article/ALeqM5gtoV0Ewth7WzM6Fzi8nUvyzyJB8Q.
4. Amin AA, Kowaro GO. Antimalaria Drug Quality in Africa. J Cli Pharm Ther. 2007;32:429–440.
5. Amin AA, Snow RW, Kokwaro GO. The quality of sulfadoxine-pyrimethamine and amodiaquine in the Kenyan retail sector. J Clin Pharm Ther. 2005;30:559–65.
6. Amon JJ. Dangerous medicines: unproven AIDS cures and counterfeit antiretroviral drugs. Glob Health. 2008;4:5.
7. Atemnkeng MA, De Cock K, Plaizier-Vercammen J. Quality control of active ingredients in artemisinin-derivative antimalarials within Kenya and DR Congo. Trop Med Int Health. 2007;12:68–74.
8. Attaran A, Bate R. Deadly Fake Medicines. 2012. New York Times, November 20.
9. Bate R. Making a killing: the deadly implications of the counterfeit drug trade. Washington, D.C.: The AEI Press; 2008.
10. Bate R, Coticelli P, Tren R, Attaran A. Antimalarial drug quality in the most severely malarious parts of Africa—a six country study. PLoS ONE. 2008;3, e2132.
11. Baumgartner FR, Jones BD. Agendas and instability in American politics. Chicago: University of Chicago Press; 1993.
12. Cerny P. From ‘iron triangles’ to ‘golden pentangles’? Globalizing the policy process. Glob Gov. 2001;7(4):397–410.
13. Chepkwony HK, Mwaura N, Guantai E, Gathoni E, Kamau FN, Mbae E, et al. Quality of antimalarial drugs analysed in the National Quality Control Laboratory during the period 2002–2005. East Cent Afr J Pharm Sci. 2007;10:59–62.
14. Chorev N. Political and institutional maneuvers in international trade negotiations: the United States and the Doha development round. In: Blaas W, Becker J, editors. Strategic arena switching in international trade negotiations. Aldershot: Ashgate; 2006.
15. Chorev N. Changing global norms through reactive diffusion: the case of intellectual property protection of AIDS drugs. Am Sociol Rev. 2012a;77(5):1–23.
16. Chorev N. The World Health Organization between north and south. Ithaca: Cornell University Press; 2012b.
17. Cockburn P, Newton PN, Agyarko EK, Akunyili D, White NJ. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med. 2005;2, e100.
18. Correa C. Implications of bilateral free trade agreements on access to medicines. Bull World Health Organ. 2006;401.
19. Deere C. The implementation game: the TRIPS agreement and the global politics of intellectual property reform in developing countries. London: Oxford University Press; 2008.
20. Drahos P. Four lessons for developing countries from the trade negotiations over access to medicines. Liverpool Law Rev. 2007;28:11.
21. Drahos P. The global governance of knowledge: patent offices and their clients. Cambridge: Cambridge University Press; 2010.
22. Editorial. The Problem of Fake and Useless Drugs. 2012. New York Times, November 21.
23. Helfer LR. Regime shifting: the TRIPS agreement and new dynamics of international intellectual property lawmaking. Yale J Int Law. 2004;29(1):1–83.
24. Kapstein EB, Busby JW. AIDS drugs for all: social movements and market transformations. Cambridge: Cambridge University Press; 2013.
25. Keck ME, Sikkink K. Activists beyond borders: advocacy networks in international politics. Ithaca: Cornell University Press; 1998.
26. Kermani F. European generics industry throws its weight behind IMPACT. 2012. Scrip. April 8. Available at http://lists.essential.org/pipermail/ip-health/2010-May.txt.
27. Kibwage IO, Ngugi JK. Sulphadoxine⁄pyrimethamine tablet products on the Kenyan market: quality concerns. East Cent Afr J Pharm Sci. 2000;3:14–9.
28. Kimani D. Illegally Imported, Fake Drugs Flood Kenya. 2004. The East African. 10 May.
29. Kimani D. Anti-Fakes Bill Threatens Access to Generics. 2008. The East African. 6 September.
30. Lewis-Lettington R, Munyi P. Willingness and Ability to Use TRIPs Flexibilities: Kenya Case Study. DFID; 2004.
31. Mahoney J. Path dependence in historical sociology. Theory Soc. 2000;29:507–48.
32. Mey BP. Unfettered consumer access to affordable therapies in the post-TRIPS era: a dead-end journey for patients? Kenya and India case studies. J World Intellect Prop. 2010;13(3):403–73.
33. Ministry of Health, WHO and Health Action International. Antimalarial medicines in Kenya: Availability, quality and registration status, December 2007.
34. Ministry of Medical Services and the Ministry of Public Health. Reforming the Pharmaceutical Sector to Ensure Equitable Access to Essential Medicines and Essential Health Technologies for all Kenyans. Sessional Paper on National Pharmaceutical Policy. Nairobi: Kenya; 2010.
35. MSF. Press Release. Critical moment for Kenyan industrial property bill. 2001a. May 10 Available at http://www.msf.org/article/critical-moment-kenyan-industrial-property-bill.
36. MSF. Press Release. Every Day Parliament Delays Passing IP Bill, 700 More Die of AIDS in Kenya. 2001b. June 5. Available at http://www.msfaccess.org/our-work/hiv-aids/article/489.
37. MSF. Fatal Confusion: How Kenya’s 2008 Anti-Counterfeit Bill Endangers Access to Medicines. A Médecins Sans Frontières Briefing Document; 2008.
38. MSF. Fatal Flaws: How Kenya’s 2008 Anti-Counterfeit Act Could Endanger Access to Medicines. A Médecins Sans Frontières briefing document; 2010.
39. Musungu S, Oh C. The use of flexibilities in TRIPS by developing countries: can they promote access to medicines? Geneva: South Centre and the World Health Organization; 2006.
40. Nayyar GML, Breman JG, Newton PN, Herrington J. Poor-quality antimalarial drugs in Southeast Asia and sub-Saharan Africa. Lancet. 2012;12:488–96.
41. Neondo H. Kenyan High Court set to make landmark decision on access to generic medicines. African Science New; 2012.
42. Newton PN, et al. Poor Quality Vital Anti-Malarials in Africa - An Urgent Neglected Public Health Priority. Malaria Journal. 2011;10:352.
43. O’Brien R, Goetz AM, Scholte JA, Williams M, editors. Contesting global governance: multilateral economic institutions and global social movements. Cambridge: Cambridge University Press; 2000.
44. Orwa JA, Keter K, Ouko PA, Kibwage O, Rukunga M. Influence of manufacturing practices on quality of pharmaceutical products manufactured in Kenya. East Afr Med J. 2004;81(6):287–92.
45. Outterson K, Smith R. Counterfeit drugs: the good, the bad and the ugly. Albany Law J Sci Technol. 2006;16:525–43.
46. Pharma Focus Asia. Counterfeit Drugs: The Issue of Key Concern and its impact on Indian Pharma Industry; 2009.
47. Pierson P. Increasing returns, path dependence, and the study of politics. Am Polit Sci Rev. 2000;94:251–68.
48. Rosenau JN. Governing the ungovernable: the challenge of a global disaggregation of authority. Regul Gov. 2007;1:88–97.
49. Rosenau JN, Czempiel E-O, editors. Governance without government: order and change in world politics. Cambridge: Cambridge University Press; 1992.
50. Schneiberg M, Bartley T. Organizations, regulation, and economic behavior: regulatory dynamics and forms from the nineteenth to twenty-first century. Annu Rev Law Soc Sci. 2008;4:31–61.
51. Sell S. Private power, public law: the globalization of intellectual property rights. Cambridge: Cambridge University Press; 2003.
52. Sell S. TRIPS was never enough: vertical forum shifting, FTAs, ACTA, and TPP. J Intellect Prop Law. 2011;18:447–78.
53. Sell S. The Global IP Upward Ratchet, Anti-Counterfeiting and Piracy Enforcement Efforts: The State of Play. 2010. PIJIP Research Paper no. 15. Washington, DC: American University Washington College of Law
54. Sell SK, Prakash A. Using ideas strategically: the contest between business and NGO networks in intellectual property rights. Int Stud Q. 2004;48:143–75.
55. Sewell Jr WH. Three temporalities: towards an eventful sociology. In: McDonald TJ, editor. The historic turn in the human sciences. Ann Arbor: University of Michigan Press; 1996.
56. Shadlen KC. Patents and pills, power and procedure: the north–south politics of public health in the WTO. Stud Comp Int Dev. 2004;39(3):76–108.
57. Shadlen KC. The politics of patents and drugs in Brazil and Mexico: the industrial bases of health policies. Comp Polit. 2009;42(1):41–58.
58. Shakoor O, Taylor RB, Behrens RH. Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health. 1997;2(9):839–45.
59. Sihanya B. Patents, Parallel Importation and Compulsory Licensing of HIV/AIDS Drugs: The Experience of Kenya. Managing The Challenges Of WTO Participation: Case Study 19. 2005. Available at http://www.wto.org/english/res_e/booksp_e/casestudies_e/case19_e.htm.
60. Siringi S. Generic drugs battle moves from South Africa to Kenya. Lancet. 2001a;357:1600.
61. Siringi S. Kenya allows parallel importation of drugs. Lancet. 2001b;357:2034.
62. Tai E. Counterfeit Medicines in Kenya. 2011. Pfizer. http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CCsQFjAA&url=http%3A%2F%2Fwww.pfizer.com%2Ffiles%2Fresponsibility%2Fglobal_health%2Felaine_tai.pdf&ei=as-8UqXQH4nokAf2roGQDQ&usg=AFQjCNGOnUM8O0TDlgdgB6LtQy04pbWsGQ&bvm=bv.58187178,d.eW0.
63. Thambisetty S. Timing, continuity, and change in the patent system. In: Haunss S, Shadlen KC, editors. The politics of intellectual property. Northhampton: Edward Elgar; 2009.
64. Third World Network. TWN Info Service on Intellectual Property Issues. 2009. 16 January. http://www.twnside.org.sg/title2/intellectual_property/info.service/2009/twn.ipr.info.090101.htm.
65. Thoithi GN, Abuga KO, Nguyo JM, Mukindia G, Kingondu O, Ngugi JK, et al. Drug quality control work in drug analysis and research unit: observation during 1996–2000. East Cent Afr J Pharm Sci. 2002;5(1):28–32.
66. Thoithi G, Abuga K, Nguyo J, et al. Drug quality control in Kenya: observation in the drug analysis and research unit during the period 2001–2005. East Cent Afr J Pharm Sci. 2008;11:74–81.
67. Unnikrishnan CH. Indian Drug Makers Worried by East Africa’s Legal Proposals. 2010. LiveMint, Feb 16.
68. Wadham N. Kenya Pressured To Implement Anti-Counterfeit Law Despite Access Fears. 2009. Intellectual Property Watch. Available at http://www.ip-watch.org/weblog/2009/07/02/kenya-pressured-to-implement-anti=−counterfeit-law-despite-access-fears/.
69. World Health Organization. Counterfeit drugs—Report of a WHO/IFPMA Workshop, 1992. WHO/DMP/CFD/92. Geneva: World Health Organization; 1992.
70. World Health Organization. The dangers of counterfeit and substandard active pharmaceutical ingredients. WHO Drug Inf. 1997;11(3):123–7.
71. World Health Organization. Report of the International Workshop on Counterfeit Drugs. WHO/DRS/CFD/98.1. Geneva: World Health Organization; 1998.
72. World Health Organization. The quality of antimalarials. A study in selected African countries. Geneva: World Health Organization; 2003.
73. World Health Organization. Survey of the quality of antiretroviral medicines circulating in selected African countries. Geneva: World Health Organization; 2007.
74. World Health Organization. Experience with Supporting Pharmaceutical Policies and Systems in Kenya: Progress, Lessons and the Role of WHO. WHO/EMP/MPC/2010.2.; 2010a.
75. World Health Organization. Preliminary Unedited Draft. Preliminary Draft Survey on National Legislation on Counterfeit Medicines. Working document WHO/ACM/1.; 2010b.
76. World Health Organization. Survey of the Quality of Selected Antimalarial Medicines Circulating in Six Countries of Sub-Saharan Africa; 2011.